- Home
- CLDX vs TNDM Comparison
CLDX vs TNDM Comparison
Compare CLDX & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- TNDM
- Stock Information
- Founded
- CLDX 1983
- TNDM 2006
- Country
- CLDX United States
- TNDM United States
- Employees
- CLDX N/A
- TNDM N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TNDM Medical/Dental Instruments
- Sector
- CLDX Health Care
- TNDM Health Care
- Exchange
- CLDX Nasdaq
- TNDM Nasdaq
- Market Cap
- CLDX 1.7B
- TNDM 1.9B
- IPO Year
- CLDX 2008
- TNDM 2013
- Fundamental
- Price
- CLDX $20.14
- TNDM $18.18
- Analyst Decision
- CLDX Buy
- TNDM Buy
- Analyst Count
- CLDX 7
- TNDM 15
- Target Price
- CLDX $55.67
- TNDM $46.07
- AVG Volume (30 Days)
- CLDX 714.4K
- TNDM 2.5M
- Earning Date
- CLDX 05-05-2025
- TNDM 05-01-2025
- Dividend Yield
- CLDX N/A
- TNDM N/A
- EPS Growth
- CLDX N/A
- TNDM N/A
- EPS
- CLDX N/A
- TNDM N/A
- Revenue
- CLDX $7,020,000.00
- TNDM $940,203,000.00
- Revenue This Year
- CLDX N/A
- TNDM $8.70
- Revenue Next Year
- CLDX $27.01
- TNDM $11.06
- P/E Ratio
- CLDX N/A
- TNDM N/A
- Revenue Growth
- CLDX 1.99
- TNDM 25.74
- 52 Week Low
- CLDX $18.61
- TNDM $17.64
- 52 Week High
- CLDX $47.00
- TNDM $53.69
- Technical
- Relative Strength Index (RSI)
- CLDX 41.83
- TNDM 22.33
- Support Level
- CLDX $18.95
- TNDM $17.64
- Resistance Level
- CLDX $21.85
- TNDM $19.35
- Average True Range (ATR)
- CLDX 1.39
- TNDM 1.58
- MACD
- CLDX 0.08
- TNDM -0.56
- Stochastic Oscillator
- CLDX 38.64
- TNDM 3.09
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.